Endothelin B receptor promotes the proliferation and immune escape of malignant gliomas
Source abstract
Abstract
PURPOSE: As a kind of difficult to cure tumour, malignant gliomas have attracted widespread attention. The proliferation and immune escape of tumour cells were closely related to the development of malignant gliomas. The aim of this study was to investigate the role of endothelin B receptor (NTBR) in gliomas. METHODS: RT-PCR was used to detect the expression of NTBR mRNA in glioma tissue and glioma cell lines. The expression of NTBR in glioma tissues was detected by immunohistochemistry. MTT assay was used to detect the viability of U87 cells after adding NTBR. Cell cloning assay was used to detect the cell proliferation ability. Western blot was used to detect the expression of TGF-β and the expression of Treg after adding NTBR to U87. RESULT: The expression of NTBR in glioma tissues and cells was significantly higher than that in the control group by RT-PCR. After adding NTBR, cell proliferation of U87 was significantly enhanced and TGF-β and Treg were significantly expressed. It was suggested that NTBR could contribute to tumour immune escape in glioma, and it was found that there was a positive correlation between NTBR expression and different stages in malignant gliomas. CONCLUSION: Endothelin B receptor can increase the proliferation of glioma cells and tumour immune escape. The expression of endothelin B is closely related to the clinical stage of glioma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nitric Oxide and Endothelin Effects · Glioma Diagnosis and Treatment · Caveolin-1 and cellular processes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurosurgery, The General Hospital of Shenyang Military, Shenyang, Liaoning, China
References (22)
Show source-provided references
1. 10.1080/21691401.2017.134592310.1080/21691401.2017.1345923 ↗
2. Xu Y, Xu W, Lu T, et al. miR-126 affects the invasion and migration of glioma cells through GATA4. Artif Cells Nanomed Biotechnol. 2016;6:1247–1253.
3. 10.1038/nature0961310.1038/nature09613 ↗
4. 10.1016/j.neo.2014.06.00310.1016/j.neo.2014.06.003 ↗
5. 10.1056/NEJMoa131252410.1056/NEJMoa1312524 ↗
6. 10.1038/nn.420110.1038/nn.4201 ↗
7. 10.1016/B978-0-12-385061-4.00001-510.1016/B978-0-12-385061-4.00001-5 ↗
8. 10.1016/j.cellsig.2010.05.00210.1016/j.cellsig.2010.05.002 ↗
9. 10.1097/HJH.000000000000134410.1097/HJH.0000000000001344 ↗
10. 10.3324/haematol.2016.15686910.3324/haematol.2016.156869 ↗
11. 10.14814/phy2.1307710.14814/phy2.13077 ↗
12. 10.1016/j.joca.2017.02.73110.1016/j.joca.2017.02.731 ↗
13. 10.1016/j.tem.2007.09.00210.1016/j.tem.2007.09.002 ↗
14. Griswold DE · Mol Pharmacol · 1999 · 56 · 80710.1016/S0026-895X(24)12544-8 ↗
15. 10.1016/S0002-9440(10)64807-910.1016/S0002-9440(10)64807-9 ↗
16. 10.1016/j.ctrv.2010.02.00910.1016/j.ctrv.2010.02.009 ↗
17. 10.1158/1535-7163.MCT-09-003210.1158/1535-7163.MCT-09-0032 ↗
18. 10.1016/j.pharmthera.2005.11.00110.1016/j.pharmthera.2005.11.001 ↗
19. 10.1038/nri250610.1038/nri2506 ↗
20. Mansh M. · Yale J Biol Med · 2011 · 84 · 381
21. 10.1016/S0092-8674(03)00432-X10.1016/S0092-8674(03)00432-X ↗
22. 10.1007/s11481-012-9359-y10.1007/s11481-012-9359-y ↗